MedTrace Logo

Clinical Study of WT2725 in Patients With Advanced Malignancies

NCT01621542 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-07-17

Study results available
· View outcomes & findings →

Summary

This clinical study is designed to evaluate the safety, immunogenicity and antitumor activity of WT2725. WT2725 will be administered to patients with advanced malignancies known to overexpress WT1

Conditions

Interventions

BIOLOGICAL

WT2725

WT2725 injection Study drug will be administered every 1-4 weeks

Sponsors & Collaborators

  • Sumitomo Pharma Co., Ltd.

    collaborator INDUSTRY

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Principal Investigators

  • Vice President Clinical Development and Medical Affairs, MD · Sumitomo Pharma America, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2017-05-17
Completion
2017-05-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01621542 on ClinicalTrials.gov